Alpha-橙色素 | 650-69-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: Alpha-橙色素
• 中文别名: Α-橙色素；Β-柠檬啉/宁乌素
• 英文名称: (3R)-3-hydroxy-8'-apo-β-caroten-8'-al
• 英文别名: apo-8'-zeaxanthinal；β-Citraurin；β-Citraurin, 3-Hydroxy-β-apo-8'-carotinal；trans-β-Citraurin；beta-Citraurin；(2E,4E,6E,8E,10E,12E,14E,16E)-17-[(4R)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-2,6,11,15-tetramethylheptadeca-2,4,6,8,10,12,14,16-octaenal
• CAS: 650-69-1
• 化学式: C₃₀H₄₀O₂
• 分子量: 432.646
• InChiKey: AVPAEFHIEZLSLZ-QCPGYTKSSA-N

物化性质

• 熔点：
  147°
• 沸点：
  486.26°C (rough estimate)
• 密度：
  1.0423 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Alpha-橙色素 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 β-Citraurol
  参考文献：
  名称：

  柑橘类胡萝卜素。2. Mitteilung。合成von（3 R）-β-Citraurin，（3 R）-β-Citraurol和（3 R）-β-Citraurinin; 柑橘类胡萝卜素的认可度† ‡

  摘要：

  柑橘类胡萝卜素。（3R）-β-Citraurin，（3R）-β-Citraurol和（3R）-β-Citraurinene的合成；柑橘类胡萝卜素构型的确定

  DOI：

  10.1002/hlca.19800630604
• 作为产物：
  描述：

  (3R)-3-Acetoxy-β-ionon 在 氢氧化钾 、 sodium hydroxide 、 sodium 、 magnesium 、 溶剂黄146 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 37.0h， 生成 Alpha-橙色素
  参考文献：
  名称：

  柑橘类胡萝卜素。2. Mitteilung。合成von（3 R）-β-Citraurin，（3 R）-β-Citraurol和（3 R）-β-Citraurinin; 柑橘类胡萝卜素的认可度† ‡

  摘要：

  柑橘类胡萝卜素。（3R）-β-Citraurin，（3R）-β-Citraurol和（3R）-β-Citraurinene的合成；柑橘类胡萝卜素构型的确定

  DOI：

  10.1002/hlca.19800630604

文献信息

• Total synthesis of myxol and deoxymyxol stereoisomers and their application to determining the absolute configurations of the natural products
  作者：Yumiko Yamano、Miki Masumoto、Shinichi Takaichi、Akimori Wada

  DOI：10.1016/j.tet.2018.02.018

  日期：2018.3

  total synthesis of myxol stereoisomers 1a,b and deoxymyxol (plectaniaxanthin) stereoisomers 2a,b was accomplished by Wittig reaction of (S)- and (R)-C10-phosphonium salts 8a,b bearing a silyl-protected 1,2-dihydroxy-ψ end group with C30-apocarotenals 6 and 7. The phosphonium salts 8a,b were derived from aldehydes 11a,b possessing a cyclopentylidene ketal moiety, prepared via Sharpless asymmetric epoxidation

  通过带有甲硅烷基保护的1,2-的（S）-和（R）-C 10 -phosph盐8a，b的Wittig反应，完成了myxol立体异构体1a，b和deoxymyxol（plectaniaxanthin）立体异构体2a，b的总合成。具有C 30-环戊烯基6和7的二羟基-ψ端基。via盐8a，b衍生自具有环戊叉基缩酮部分的醛11a，b，其通过烯丙醇12的Sharpless不对称环氧化制备。接着是环氧乙烷环的区域选择性裂解。我们建立了使用手性柱分离立体异构体1a，b和2a，b的分析HPLC方法，从而确定了天然产物的绝对构型。HPLC分析确定了既myxol和deoxymyxol从细菌中分离具有2'小号-构型。
• Carotenoid analogs or derivatives for controlling connexin 43 expression
  申请人：Lockwood Fournier Samuel

  公开号：US20050009930A1

  公开（公告）日：2005-01-13

  A method of controlling (e.g., influencing or affecting) connexin 43 expression in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. In some embodiments, controlling connexin 43 expression in a subject may effectively treat cardiac arrhythmia and/or cancerous and pre-cancerous cells in a subject. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

  在一个主体中控制（例如，影响或影响）连接蛋白43表达的方法可能包括向该主体施用有效量的药学上可接受的配方。在某些实施例中，控制主体中连接蛋白43的表达可能有效治疗心律失常和/或癌症和癌前细胞。药学上可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共抗氧化剂配方结合使用。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括至少一个取代基的非环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。
• Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050004235A1

  公开（公告）日：2005-01-06

  A method of treating liver disease in a subject. The method may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include an acyclic alkene including at least one substituent and/or a cyclic ring including at least one substituent. In some embodiments, a carotenoid analog or derivative may include at least one substituent.

  一种治疗主体肝病的方法。该方法可能包括向主体施用有效量的药学上可接受的配方。药学上可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯烃。共轭聚烯烃可能包括至少一个取代基的无环烯烃和/或至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物可能包括至少一个取代基。
• Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
  申请人：Lockwood Fournier Samuel

  公开号：US20050009758A1

  公开（公告）日：2005-01-13

  A method for inhibiting and/or ameliorating the occurrence of diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals in a subject whereby a subject is administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The analog or derivative is administered such that the subject's risk of experiencing diseases associated with reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals may be thereby reduced. The analog or analog combination may be administered to a subject for the inhibition and/or amelioration of any disease that involves production of reactive oxygen species, reactive nitrogen species, radicals and/or non-radicals. In some embodiments, the invention may include a chemical compound including an at least partially water soluble carotenoid analog or derivative. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种抑制和/或改善与主体中的活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病发生的方法，其中向主体施用类胡萝卜素类似物或衍生物，单独或与另一类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类似物或衍生物的施用使得主体发生与活性氧化物种、活性氮物种、自由基和/或非自由基相关疾病的风险可能降低。类似物或类似物组合可用于抑制和/或改善涉及活性氧化物种、活性氮物种、自由基和/或非自由基产生的任何疾病。在某些实施例中，该发明可能包括一种包括至少部分水溶性类胡萝卜素类似物或衍生物的化合物。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。该取代基可能通过醚功能基与环状环相耦合。
• Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
  申请人：Lockwood Fournier Samuel

  公开号：US20050049248A1

  公开（公告）日：2005-03-03

  A method of controlling (e.g., influencing or affecting) C-reactive protein levels in a subject may include administering to the subject an effective amount of a pharmaceutically acceptable formulation. The pharmaceutically acceptable formulation may include a synthetic analog or derivative of a carotenoid. The subject may be administered a carotenoid analog or derivative, either alone or in combination with another carotenoid analog or derivative, or co-antioxidant formulation. The carotenoid analog may include a conjugated polyene with between 7 to 14 double bonds. The conjugated polyene may include a cyclic ring including at least one substituent. In some embodiments, a cyclic ring of a carotenoid analog or derivative may include at least one j e substituent. The substituent may be coupled to the cyclic ring with an ether functionality.

  一种控制（例如，影响或影响）主体中C-反应蛋白水平的方法可能包括向主体施用有效量的药用可接受的配方。药用可接受的配方可能包括类胡萝卜素的合成类似物或衍生物。可以向主体施用类胡萝卜素类似物或衍生物，单独或与另一种类胡萝卜素类似物或衍生物或共抗氧化剂配方结合。类胡萝卜素类似物可能包括具有7到14个双键的共轭聚烯。共轭聚烯可能包括包括至少一个取代基的环状环。在某些实施例中，类胡萝卜素类似物或衍生物的环状环可能包括至少一个取代基。取代基可能通过醚功能与环状环偶联。